| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Upstream Bio, Inc.
13G/A
Amendment 2
UPB · 91678A107
|
4.9% |
10/29/2026
Event 9/30/2026
|
|||
| Decheng Capital Global Life Sciences Fund IV, L.P. | 4.9% | ||||
| Decheng Capital Management IV (Cayman), LLC | 4.9% | ||||
| Xiangmin Cui | 4.9% | ||||
|
Upstream Bio, Inc.
13G/A
Amendment 1
UPB · 91678A107
|
5.0% |
5/15/2026
Event 3/31/2026
|
|||
| Decheng Capital Global Life Sciences Fund IV, L.P. | 5.0% | ||||
| Decheng Capital Management IV (Cayman), LLC | 5.0% | ||||
| Decheng Capital Global Healthcare Fund (Master), LP | 0% | ||||
| Decheng Capital Global Healthcare GP, LLC | 0% | ||||
| Xiangmin Cui | 5.0% | ||||
|
Aardvark Therapeutics, Inc.
13G
0029421007
|
18.3% |
2/24/2025
Event 2/14/2025
|
|||
| Decheng Capital Global Life Sciences Fund IV, L.P. | 13.8% | ||||
| Decheng Capital Management IV (Cayman), LLC | 13.8% | ||||
| Decheng Capital Global Healthcare Fund (Master), LP | 4.5% | ||||
| Decheng Capital Global Healthcare GP, LLC | 4.5% | ||||
| Xiangmin Cui | 18.3% | ||||
|
CG Oncology, Inc.
13G/A
Amendment 2
CGON · 156944100
|
8.4% |
2/14/2025
Event 12/31/2024
|
|||
| Decheng Capital Global Life Sciences Fund IV, L.P. | 7.0% | ||||
| Decheng Capital Management IV (Cayman), LLC | 7.0% | ||||
| Decheng Capital Global Healthcare Fund (Master), LP | 1.4% | ||||
| Decheng Capital Global Healthcare GP, LLC | 1.4% | ||||
| Xiangmin Cui | 8.4% | ||||
|
Upstream Bio, Inc.
13G
UPB · 91678A107
|
6.1% |
2/14/2025
Event 12/31/2024
|
|||
| Decheng Capital Global Life Sciences Fund IV, L.P. | 5.8% | ||||
| Decheng Capital Management IV (Cayman), LLC | 5.8% | ||||
| Decheng Capital Global Healthcare Fund (Master), LP | 0.4% | ||||
| Decheng Capital Global Healthcare GP, LLC | 0.4% | ||||
| Xiangmin Cui | 6.1% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.